Targeted Therapy of Ewing's Sarcoma

Table 1

Insulin-like growth factor 1 receptor monoclonal antibodies against Ewing’s sarcoma.

Drug	Manufacturer	Current status	Reference
R1507	Roche	PC	[9, 25, 26]
CP-751,871; (figitumumab)	Pfizer	PC	[7]
AMG-479	Amgen	C	[8, 27]
SCH-717454; (robatumumab)	Schering-Plough	PC*	[24]
IMC-A12; (cixutumumab)	Imclone	A+	[28]
MK-0646	Merck	A+	[29]
BIIB022	Biogen Idec	A	[30]
AVE-1642	Sanofi-Aventis	A	[31]

*PC: permanently closed; C: closed; A, accruing; A+: accruing combination trials and/or additional future trials in development.